Lonza has appointed former Novartis executive Philippe Deecke as its new
U.S. grocery chain Kroger Co (KR.N) is gearing up to administer 1 million COVID-19 booster shots a week once they are available to the general public, and plans to offer vaccines in nursing homes for those who cannot go to its stores.
A member of the Sackler family that owns Purdue Pharma testified on Tuesday that his family bears a “moral responsibility” to help abate the U.S. opioid crisis but said it will not contribute financially to the effort unless it receives broad legal protections.
Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co (MRK.N) spinoff, Organon & Co (OGN.N).
PharmaCann, one of the 10 original cannabis licensees in New York, has confidentially filed for an initial public offering that could value it at well over $1 billion, sources familiar with the matter told Reuters.
Shares of Pfizer Inc (PFE.N) hit a record high on Tuesday for the first time in more than 20 years as shares of COVID-19 vaccine makers have surged amid rising coronavirus cases in the United States.
Deutsche Bank AG (DBKGn.DE) has hired two new managing directors for its healthcare investment banking team in the United States, according to an internal memo seen by Reuters, as the bank looks to double down on healthcare dealmaking.
BioNTech and partner Pfizer (PFE.N) have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca (AZN.L), the German biotech group said on Monday.
Merck KGaA (MRCG.DE) raised its outlook after posting forecast-beating second quarter profits on Thursday, boosted by demand for its lab gear and supplies from pharma companies making treatments and vaccines against the coronavirus.
CVS Health Corp (CVS.N) on Wednesday hedged a bit on its long-term target for double-digit earnings growth for next year, pointing to uncertainty around COVID-19 vaccination and testing demand, as well as medical costs, sending shares down 3%.
Lonza has appointed former Novartis executive Philippe Deecke as its new
U.S. grocery chain Kroger Co (KR.N) is gearing up to administer 1 million COVID-19 booster shots a week once they are available to the general public, and plans to offer vaccines in nursing homes for those who cannot go to its stores.
A member of the Sackler family that owns Purdue Pharma testified on Tuesday that his family bears a “moral responsibility” to help abate the U.S. opioid crisis but said it will not contribute financially to the effort unless it receives broad legal protections.
Warren Buffett’s Berkshire Hathaway Inc (BRKa.N) said on Monday it trimmed or eliminated its stakes in several pharmaceutical companies, and reported a small new stake in a Merck & Co (MRK.N) spinoff, Organon & Co (OGN.N).
PharmaCann, one of the 10 original cannabis licensees in New York, has confidentially filed for an initial public offering that could value it at well over $1 billion, sources familiar with the matter told Reuters.
Shares of Pfizer Inc (PFE.N) hit a record high on Tuesday for the first time in more than 20 years as shares of COVID-19 vaccine makers have surged amid rising coronavirus cases in the United States.
Deutsche Bank AG (DBKGn.DE) has hired two new managing directors for its healthcare investment banking team in the United States, according to an internal memo seen by Reuters, as the bank looks to double down on healthcare dealmaking.
BioNTech and partner Pfizer (PFE.N) have supplied more than one billion doses of their COVID-19 vaccine as per July 21, a bigger number than delivered by competitor AstraZeneca (AZN.L), the German biotech group said on Monday.
Merck KGaA (MRCG.DE) raised its outlook after posting forecast-beating second quarter profits on Thursday, boosted by demand for its lab gear and supplies from pharma companies making treatments and vaccines against the coronavirus.
CVS Health Corp (CVS.N) on Wednesday hedged a bit on its long-term target for double-digit earnings growth for next year, pointing to uncertainty around COVID-19 vaccination and testing demand, as well as medical costs, sending shares down 3%.
© | All rights reserved.
